Defining the highest-risk clinical subgroups upon community infection with SARS-CoV-2 when considering the use of neutralising monoclonal antibodies (nMABs) and antiviral drugs: independent advisory group report - GOV.UK

Introduction At the request of the Deputy Chief Medical Officer (DCMO), an advisory group, supported by the NHS England RAPID-C19 team, was constituted to identify a set of patient conditions (or co… [+66831 chars]

full article...